mAb-话题@MedSci

#mAb#

1302篇内容 | 2838人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1912351, encodeId=4b7d1912351b8, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=CAR-T对手来了！CD19单抗tafasitamab联合来那度胺治疗淋巴瘤提交FDA上市申请, objectType=article, longId=193578, objectId=2e2f1935e8e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e2f1935e8e9, replyNumber=0, likeNumber=92, createdTime=2020-10-28, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e2f1935e8e9, moduleTitle=CAR-T对手来了！CD19单抗tafasitamab联合来那度胺治疗淋巴瘤提交FDA上市申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2e2f1935e8e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912440, encodeId=5d301912440bc, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Immunol Lett：过敏性鼻炎中Omalizumab的长期疗效如何？, objectType=article, longId=200537, objectId=472f20053e7b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=472f20053e7b, replyNumber=0, likeNumber=88, createdTime=2021-02-19, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=472f20053e7b, moduleTitle=Immunol Lett：过敏性鼻炎中Omalizumab的长期疗效如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=472f20053e7b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912472, encodeId=f85f19124e213, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=IBD: Ustekinumab剂量强化后克罗恩病治疗仍然失败的预测因子, objectType=article, longId=203049, objectId=aa44203049c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa44203049c4, replyNumber=0, likeNumber=77, createdTime=2021-06-25, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa44203049c4, moduleTitle=IBD: Ustekinumab剂量强化后克罗恩病治疗仍然失败的预测因子, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aa44203049c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912507, encodeId=5580191250e22, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=中国NMPA接受Envafolimab（KN035）治疗MSI-H / dMMR晚期实体瘤的NDA, objectType=article, longId=205086, objectId=4d4920508636, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d4920508636, replyNumber=0, likeNumber=70, createdTime=2021-05-29, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d4920508636, moduleTitle=中国NMPA接受Envafolimab（KN035）治疗MSI-H / dMMR晚期实体瘤的NDA, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d4920508636)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912320, encodeId=abc0191232054, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=BCL-2抑制剂VENCLYXTO与CD20单抗obinutuzumab的联合疗法获欧洲批准，用于未经治疗的慢性淋巴细胞白血病, objectType=article, longId=190017, objectId=0f0519001e6d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f0519001e6d, replyNumber=0, likeNumber=91, createdTime=2021-02-14, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f0519001e6d, moduleTitle=BCL-2抑制剂VENCLYXTO与CD20单抗obinutuzumab的联合疗法获欧洲批准，用于未经治疗的慢性淋巴细胞白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f0519001e6d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912308, encodeId=aea61912308db, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=JACC：evolocumab治疗家族性高胆固醇血症的远期预后研究, objectType=article, longId=188539, objectId=848d188539d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=848d188539d4, replyNumber=0, likeNumber=92, createdTime=2020-12-23, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=848d188539d4, moduleTitle=JACC：evolocumab治疗家族性高胆固醇血症的远期预后研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=848d188539d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912488, encodeId=03a6191248893, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=NEJM：Golimumab可部分恢复新发病I型糖尿病青年患者的胰岛功能, objectType=article, longId=203558, objectId=5ef12035588c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ef12035588c, replyNumber=0, likeNumber=68, createdTime=2020-12-02, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ef12035588c, moduleTitle=NEJM：Golimumab可部分恢复新发病I型糖尿病青年患者的胰岛功能, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ef12035588c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912407, encodeId=9493191240e16, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=罗氏CD20xCD3双特异性抗体Mosunetuzumab治疗滤泡性淋巴瘤，获得FDA的突破性治疗指定, objectType=article, longId=197588, objectId=c63a19e588ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c63a19e588ba, replyNumber=0, likeNumber=72, createdTime=2021-01-02, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c63a19e588ba, moduleTitle=罗氏CD20xCD3双特异性抗体Mosunetuzumab治疗滤泡性淋巴瘤，获得FDA的突破性治疗指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c63a19e588ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912469, encodeId=ffc119124695c, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Lenzilumab预防COVID-19“细胞因子风暴”：已开展III期临床试验, objectType=article, longId=202718, objectId=5865202e1851, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5865202e1851, replyNumber=0, likeNumber=87, createdTime=2021-03-30, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5865202e1851, moduleTitle=Lenzilumab预防COVID-19“细胞因子风暴”：已开展III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5865202e1851)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912390, encodeId=13f5191239021, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=FDA批准Still病的**药物：诺华的白细胞介素-1单抗canakinumab, objectType=article, longId=196063, objectId=e34d196063ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e34d196063ce, replyNumber=0, likeNumber=74, createdTime=2021-04-13, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e34d196063ce, moduleTitle=FDA批准Still病的**药物：诺华的白细胞介素-1单抗canakinumab, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e34d196063ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912372, encodeId=32cd19123e27c, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=2020EAN大会速递丨SAkura研究：Satralizumab治疗前沿 MedSci梅斯 6天前, objectType=article, longId=195297, objectId=482d19529e0f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=482d19529e0f, replyNumber=0, likeNumber=65, createdTime=2021-03-26, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=482d19529e0f, moduleTitle=2020EAN大会速递丨SAkura研究：Satralizumab治疗前沿 MedSci梅斯 6天前, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=482d19529e0f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912401, encodeId=379c1912401d9, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=泛发性脓疱型银屑病：Imsidolimab获FDA孤儿药称号, objectType=article, longId=197298, objectId=6b4219e29846, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6b4219e29846, replyNumber=0, likeNumber=78, createdTime=2021-01-07, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6b4219e29846, moduleTitle=泛发性脓疱型银屑病：Imsidolimab获FDA孤儿药称号, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6b4219e29846)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912398, encodeId=efc81912398da, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Gynecol Oncol：新诊断的卵巢癌、原发性腹膜癌和输卵管癌的静脉或腹膜内铂类化疗联合Veliparib和Bevacizumab的I期研究, objectType=article, longId=197253, objectId=32b119e253bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=32b119e253bc, replyNumber=0, likeNumber=73, createdTime=2021-02-12, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=32b119e253bc, moduleTitle=Gynecol Oncol：新诊断的卵巢癌、原发性腹膜癌和输卵管癌的静脉或腹膜内铂类化疗联合Veliparib和Bevacizumab的I期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=32b119e253bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912386, encodeId=5c3a19123867d, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=AAD 2020：Lebrikizumab治疗特应性皮炎，患者生活质量得以显著改善, objectType=article, longId=195865, objectId=2a461958655e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a461958655e, replyNumber=0, likeNumber=146, createdTime=2020-12-24, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a461958655e, moduleTitle=AAD 2020：Lebrikizumab治疗特应性皮炎，患者生活质量得以显著改善, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a461958655e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912506, encodeId=1e191912506d0, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=罗氏的Faricimab在糖尿病性黄斑水肿研究中大获成功, objectType=article, longId=205045, objectId=31af20504527, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=31af20504527, replyNumber=0, likeNumber=81, createdTime=2021-07-10, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=31af20504527, moduleTitle=罗氏的Faricimab在糖尿病性黄斑水肿研究中大获成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=31af20504527)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912454, encodeId=9de71912454e8, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=神经母细胞瘤的治疗或迎突破性进展：Nivatrotamab获得FDA“孤儿药称号”和“罕见儿科疾病称号”, objectType=article, longId=201836, objectId=84d4201836d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=84d4201836d0, replyNumber=0, likeNumber=83, createdTime=2021-05-14, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=84d4201836d0, moduleTitle=神经母细胞瘤的治疗或迎突破性进展：Nivatrotamab获得FDA“孤儿药称号”和“罕见儿科疾病称号”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=84d4201836d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912328, encodeId=56a61912328ef, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Antolimab（AK002）治疗肥大细胞胃肠道疾病：I期阳性结果, objectType=article, longId=190836, objectId=3f35190836d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f35190836d8, replyNumber=0, likeNumber=104, createdTime=2020-10-17, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f35190836d8, moduleTitle=Antolimab（AK002）治疗肥大细胞胃肠道疾病：I期阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3f35190836d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912362, encodeId=957e19123624d, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Lancet：Atezolizumab联合铂化疗一线治疗转移性尿路上皮癌, objectType=article, longId=194245, objectId=b6fe19424555, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b6fe19424555, replyNumber=0, likeNumber=82, createdTime=2020-12-09, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b6fe19424555, moduleTitle=Lancet：Atezolizumab联合铂化疗一线治疗转移性尿路上皮癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b6fe19424555)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912451, encodeId=be39191245159, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Lancet Haematol：CD20单抗Obinutuzumab联合DHAP治疗套细胞淋巴瘤的疗效, objectType=article, longId=201580, objectId=a894201580eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a894201580eb, replyNumber=0, likeNumber=87, createdTime=2020-11-17, rootId=0, userName=医者仁心, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a894201580eb, moduleTitle=Lancet Haematol：CD20单抗Obinutuzumab联合DHAP治疗套细胞淋巴瘤的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a894201580eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912457, encodeId=eeda191245e31, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=UEGW 2020：Etrolizumab治疗中重度溃疡性结肠炎，并不优于Infliximab（英夫利昔单抗）, objectType=article, longId=202070, objectId=15bb2020e093, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15bb2020e093, replyNumber=0, likeNumber=91, createdTime=2021-09-04, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15bb2020e093, moduleTitle=UEGW 2020：Etrolizumab治疗中重度溃疡性结肠炎，并不优于Infliximab（英夫利昔单抗）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=15bb2020e093)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

mAb

2020-05-29

snf701207 (审核中...)

前往app查看评论内容

#mAb#

CAR-T对手来了！CD19单抗tafasitamab联合来那度胺治疗淋巴瘤提交FDA上市申请

2020-10-28

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Immunol Lett：过敏性鼻炎中Omalizumab的长期疗效如何？

2021-02-19

snf701207 (审核中...)

前往app查看评论内容

#mAb#

IBD: Ustekinumab剂量强化后克罗恩病治疗仍然失败的预测因子

2021-06-25

snf701207 (审核中...)

前往app查看评论内容

#mAb#

中国NMPA接受Envafolimab（KN035）治疗MSI-H / dMMR晚期实体瘤的NDA

2021-05-29

snf701207 (审核中...)

前往app查看评论内容

#mAb#

BCL-2抑制剂VENCLYXTO与CD20单抗obinutuzumab的联合疗法获欧洲批准，用于未经治疗的慢性淋巴细胞白血病

2021-02-14

snf701207 (审核中...)

前往app查看评论内容

#mAb#

JACC：evolocumab治疗家族性高胆固醇血症的远期预后研究

2020-12-23

snf701207 (审核中...)

前往app查看评论内容

#mAb#

NEJM：Golimumab可部分恢复新发病I型糖尿病青年患者的胰岛功能

2020-12-02

snf701207 (审核中...)

前往app查看评论内容

#mAb#

罗氏CD20xCD3双特异性抗体Mosunetuzumab治疗滤泡性淋巴瘤，获得FDA的突破性治疗指定

2021-01-02

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Lenzilumab预防COVID-19“细胞因子风暴”：已开展III期临床试验

2021-03-30

snf701207 (审核中...)

前往app查看评论内容

#mAb#

FDA批准Still病的**药物：诺华的白细胞介素-1单抗canakinumab

2021-04-13

snf701207 (审核中...)

前往app查看评论内容

#mAb#

2020EAN大会速递丨SAkura研究：Satralizumab治疗前沿 MedSci梅斯 6天前

2021-03-26

snf701207 (审核中...)

前往app查看评论内容

#mAb#

泛发性脓疱型银屑病：Imsidolimab获FDA孤儿药称号

2021-01-07

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Gynecol Oncol：新诊断的卵巢癌、原发性腹膜癌和输卵管癌的静脉或腹膜内铂类化疗联合Veliparib和Bevacizumab的I期研究

2021-02-12

snf701207 (审核中...)

前往app查看评论内容

#mAb#

AAD 2020：Lebrikizumab治疗特应性皮炎，患者生活质量得以显著改善

2020-12-24

snf701207 (审核中...)

前往app查看评论内容

#mAb#

罗氏的Faricimab在糖尿病性黄斑水肿研究中大获成功

2021-07-10

snf701207 (审核中...)

前往app查看评论内容

#mAb#

神经母细胞瘤的治疗或迎突破性进展：Nivatrotamab获得FDA“孤儿药称号”和“罕见儿科疾病称号”

2021-05-14

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Antolimab（AK002）治疗肥大细胞胃肠道疾病：I期阳性结果

2020-10-17

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Lancet：Atezolizumab联合铂化疗一线治疗转移性尿路上皮癌

2020-12-09

医者仁心 (审核中...)

前往app查看评论内容

#mAb#

Lancet Haematol：CD20单抗Obinutuzumab联合DHAP治疗套细胞淋巴瘤的疗效

2020-11-17

snf701207 (审核中...)

前往app查看评论内容

#mAb#

UEGW 2020：Etrolizumab治疗中重度溃疡性结肠炎，并不优于Infliximab（英夫利昔单抗）

2021-09-04

科室
- - 订阅+
  - 更多科室
工具
服务